Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) and AAV-U7 rescues the severe DMD phenotype in mice

Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) and AAV-U7 rescues the severe DMD phenotype in mice

Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disease caused by an absence of the dystrophin protein, which is essential for muscle fiber integrity. Among the developed therapeutic strategies for DMD, exon skipping approach corrects the frame shift and partially restores dystrophi...

Detaylı Bibliyografya
Asıl Yazarlar:	Forand, A, Muchir, A, Mougenot, N, Sevoz-Couche, C, Peccate, C, Le Maitre, M, Izabelle, C, Wood, MJA, Lorain, S, Piétri-Rouxel, F
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Elsevier 2020

Benzer Materyaller

Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers
Yazar:: Li, Chengxi, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

MOTS‐c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice
Yazar:: Ning Ran, ve diğerleri
Baskı/Yayın Bilgisi: (2020-12-01)

Phosphorodiamidate Morpholino Oligomers-Loaded Nanobubbles for Ultrasound-Mediated Delivery to the Myocardium in Muscular Dystrophy
Yazar:: Yoko Endo-Takahashi, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study
Yazar:: Cirak, S, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
Yazar:: Cirak, S, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy
Yazar:: Le Hir, M, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Endo-Porter–mediated delivery of phosphorodiamidate morpholino oligos (PMOs) in erythrocyte suspension cultures from Cope's gray treefrog Hyla chrysoscelis
Yazar:: Venkateshwar Mutyam, ve diğerleri
Baskı/Yayın Bilgisi: (2011-05-01)

PPMO's as therapeutic modulators for myotonic dystrophy type 1
Yazar:: Holland, A, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Rescu of severely affected dystrophin/utrophin deficient mice by morpholino-oligomer mediated exon skipping
Yazar:: Goyenvalle, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
Yazar:: Goyenvalle, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Dystrophin Threshold Level Necessary for Normalization of Neuronal Nitric Oxide Synthase, Inducible Nitric Oxide Synthase, and Ryanodine Receptor-Calcium Release Channel Type 1 Nitrosylation in Golden Retriever Muscular Dystrophy Dystrophinopathy
Yazar:: Gentil, C, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Guidelines for morpholino use in zebrafish
Yazar:: Stainier, Didier Y. R., ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model
Yazar:: Juri Hasegawa, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA
Yazar:: Alexandra Sakai, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Corrosion studies of Inconel 617 in high temperature air and He-ppmO2 atmospheres
Yazar:: Haoxiang Li, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Lessons learned from vivo-morpholinos: How to avoid vivo-morpholino toxicity
Yazar:: David P. Ferguson, ve diğerleri
Baskı/Yayın Bilgisi: (2014-05-01)

DMD and West syndrome
Yazar:: Cardas, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency
Yazar:: Yin, HF, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
Yazar:: Kinali, M, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Vivo-Morpholinos: A non-peptide transporter delivers Morpholinos into a wide array of mouse tissues
Yazar:: Paul A. Morcos, ve diğerleri
Baskı/Yayın Bilgisi: (2008-12-01)

Higher baseline heart rate variability in CCHS patients with progestin-associated recovery of hypercapnic ventilatory response
Yazar:: Caroline Sevoz-Couche, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

Analysis of DMD translocations
Yazar:: Cockburn, D, ve diğerleri
Baskı/Yayın Bilgisi: (1991)

Comparative phosphoproteomics of zebrafish Fyn/Yes morpholino knockdown embryos.
Yazar:: Lemeer, S, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.
Yazar:: Koenig, M, ve diğerleri
Baskı/Yayın Bilgisi: (1987)

P740: DMD or not DMD? Clinical genome sequencing in the interpretation of complex copy number gains
Yazar:: Edward Higginbotham, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Peptide nucleic acids, morpholinos and related antisense biomolecules /
Yazar:: 204120 Janson, Christopher G., ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Guidelines for Corticosteroid use in Treatment of DMD
Yazar:: Vamshi K. Rao
Baskı/Yayın Bilgisi: (2016-07-01)

The use of Endo-Porter to deliver morpholinos in kidney organ culture
Yazar:: George N. Nikopoulos, ve diğerleri
Baskı/Yayın Bilgisi: (2008-04-01)

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD
Yazar:: Pichavant, C, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.
Yazar:: Pichavant, C, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
Yazar:: Godfrey, C, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Affinity Purification of RNA: Sequence-Specific Capture by Nonionic Morpholino Probes
Yazar:: J.M. Wages, ve diğerleri
Baskı/Yayın Bilgisi: (1997-12-01)

Comprehensive RNA-sequencing analysis in serum and muscle reveals novel small RNA signatures with biomarker potential for DMD
Yazar:: Coenen-Stass, AML, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

A dinucleotide repeat polymorphism at the DMD locus.
Yazar:: Powell, J, ve diğerleri
Baskı/Yayın Bilgisi: (1991)

Muscular dystrophy associated with the DMD gene in women
Yazar:: E. O. Vorontsova, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Bessel_DMD: the numerical code based on the scalar Fresnel–Kirchhoff integration to calculate the diffraction and bessel-like beam by using the DMD
Yazar:: Pei, Ting-Han, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice.
Yazar:: Rafael, J, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

A female patient carrying a novel DMD mutation with non-random X-chromosome inactivation from a DMD family
Yazar:: Ming-Xia Sun, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

Delaying Gal4-driven gene expression in the zebrafish with morpholinos and Gal80.
Yazar:: Adèle Faucherre, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

Second-generation compound for the modulation of utrophin in the therapy of DMD
Yazar:: Guiraud, S, ve diğerleri
Baskı/Yayın Bilgisi: (2015)